Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting

18Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Molecules involved in drug resistance can be targeted for better therapeutic efficacies. Research on midkine (MDK) has escalated in the last few decades, which affirms a positive correlation between disease progression and MDK expression in most cancers and indicates its association with multi-drug resistance in cancer. MDK, a secretory cytokine found in blood, can be exploited as a potent biomarker for the non-invasive detection of drug resistance expressed in various cancers and, thereby, can be targeted. We summarize the current information on the involvement of MDK in drug resistance, and transcriptional regulators of its expression and highlight its potential as a cancer therapeutic target.

Cite

CITATION STYLE

APA

Saikia, M., Cheung, N., Singh, A. K., & Kapoor, V. (2023, May 1). Role of Midkine in Cancer Drug Resistance: Regulators of Its Expression and Its Molecular Targeting. International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/ijms24108739

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free